Please upgrade your browser.
Carrie Konosky, the Kidney Cancer Association's Vice President of Development and Public Affairs is in Russia this week to attend an important annual cancer meeting.
Carolyn Stoutt, MSW Dept. of Supportive Care Medicine, City of Hope Nancy P. Moldawer, RN, MSN Dept. of Medical Oncology and Therapeutics Research, City of Hope
What's the role of radiation therapy in the treatment of kidney cancer? We have discovered at Roswell Park that radiation could, in fact, play a very large role. After demonstrating in the laboratory that radiation changes the immune profile of kidney cancer cells, we'll be opening an immunotherapy clinical trial to evaluate the role of radiation, followed by surgery, in the treatment of metastatic kidney cancer.
Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma - Abstract
Renal cell carcinoma (RCC), the predominant form of kidney cancer, is characterized by high resistance to radiation and chemotherapy.
Wilms tumor is a form of kidney cancer that affects children. About 1,400 children are diagnosed with cancer each year in Canada. The Kidney Cancer Association hosts http://www.WilmsKids.com and provides information and support for families dealing with this malignancy.
Congress has designated September as National Sickle Cell Awareness Month to help focus attention on the need for research and treatment of sickle cell disease. People with this trait are at risk for a specific, rare, type of kidney cancer.
A fiber-rich diet could help to protect you from kidney cancer...
The drug, called MK3475, is part of a clinical trial at the South Texas Accelerated Research Therapeutics Center, known around the world as the START center.
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus
We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.
Tyrosine kinase inhibitors with activity against vascular endothelial growth factor receptor 2 are now standard treatment for the majority of patients with advanced renal cell carcinoma.
|Powered by NeonCRM|